TPT0701

**TPT0701** is a next-generation small molecule anti-obesity drug candidate developed by Tetra Pharm Technologies, designed to address the underlying brain circuitry dysfunction in obesity rather than just its metabolic effects. It functions as a **CB1 receptor (CB1R) antagonist**, decreasing appetite, increasing satiety, and up-regulating energy metabolism by influencing the hypothalamus-hippocampal circuit that governs food intake and satiety while regulating inflammation to restore homeostasis. Originally conceptualized in 2022 for obese patients with schizophrenia, it targets impairments proportional to BMI in obese individuals and is advancing through preclinical development with proof-of-concept expected around 2024.